Generic liquid drug manufacturer Pharmaceutical Associates, Inc. (PAI), has notified 340B covered entities on the U.S. Health Resources and Services Administration (HRSA) website about 340B overcharges and potential credit/rebill repayments regarding all of its products covering the first through third
…Month: February 2021
The U.S. Health Resources and Services Administration (HRSA) is “ramping up” its work with the Biden administration “and bringing forth the key issues and concerns of” the 340B program, Rear Adm. Krista Pedley, the program’s director, said today in a
…
Drug manufacturer AstraZeneca on Friday asked the federal district judge in Delaware handling its 340B contract pharmacy lawsuit against the federal government either to issue a preliminary injunction in its favor or expedite court proceedings “to prevent imminent irreparable harm”
…
The U.S. House Energy and Commerce Committee on Friday passed pandemic-relief legislation with language that could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP). It could also result in additional
…
A Pulitzer Prize-winning journalism website that fact-checks politicians’ claims has waded into the controversy over whether President Biden raised insulin prices by freezing a 340B-related Trump administration regulation.
On Feb. 11, the Poynter Institute’s PolitiFact site rated U.S. Senate
…
Drug manufacturer Bausch Health last week said on the U.S. Health Resources and Services Administration website that its branded NDCs “will once again be available at the 340B ceiling price” through AmeriSourceBergen Corp. (ABC) “for eligible 340B purchases made by
…
The ability to generate profits through the 340B program prompts hospitals to buy physician practices and shift delivery of care to more costly hospital outpatient settings, driving up drug costs for patients and employers, Pharmaceutical Research and Manufacturers of America
…
A federal district judge in Oakland, Calif., on Tuesday expressed doubt that she had jurisdiction to require the U.S. Health and Human Services Department (HHS) to make drug manufacturers repay 340B hospitals for drug discounts that the companies have declined
…The U.S. House Energy and Commerce Committee is scheduled to mark up COVID-19 relief legislation today with language that could cause pharmaceutical manufacturers to owe states Medicaid drug rebates worth more than a drug’s average manufacturer price (AMP).
The language
…